Home / Stocks / Anuh Pharma Limited
ANUHPHR

Anuh Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹90.42

Change

-0.36 (-0.4%)

Open

₹90.0

Prev. Close

₹90.78

Day High

₹92.0

Day Low

₹89.8

Volume Analysis

Traded

79,711

Delivered

50,505

Delivery %

63.36%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (0)

No signal for this stock

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹93.88 ₹92.94 ₹91.68 ₹90.74 ₹89.48 ₹88.54 ₹87.28
Fibonacci ₹92.94 ₹92.1 ₹91.58 ₹90.74 ₹89.9 ₹89.38 ₹88.54
Camarilla ₹91.03 ₹90.82 ₹90.62 ₹90.74 ₹90.22 ₹90.02 ₹89.82

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+14.91%

1 Week

-3.46%

1 Month

+8.2%

3 Months

+11.31%

6 Months

+23.9%

1 Year

+9.02%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Anuh Pharma Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Corporate Governance (100/100), while Institutional Ownership (30/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising.

TopFund Score — Fundamentals Quality

64/100 — Average

Data confidence: 60/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Corporate Governance

100

Institutional Ownership

30

Risk & Volatility

76

Liquidity

44

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Income tax demand order of Rs 9,93,206 for AY 2018-19; company will appeal.

66th AGM on 12 Aug 2026 approved director reappointments, cost auditor reappointment, JMD pay revisions, new MOA/AOA.

At 66th AGM on 12 Aug 2026, shareholders approved director reappointments, cost auditor reappointment, and JMD remuneration revisions.

66th AGM voting results approved; Rs.1.50 dividend, director reappointments, remuneration revisions, and MoA/AoA changes passed.

Source: BSE regulatory filings, via Screener.in.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 70.59% → 71.79%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 29.4% 30.05% 29.96% 30.05% 30.06% 30.07% 30.04% 30.04% 28.19% 28.17% 28.14% 28.19%
Promoters 70.59% 69.94% 69.91% 69.91% 69.91% 69.91% 69.91% 69.91% 71.81% 71.81% 71.79% 71.79%
FII 0.0% 0.0% 0.03% 0.03% 0.02% 0.02% 0.04% 0.04% 0.0% 0.0% 0.05% 0.01%
DII 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Anuh Pharma Limited (this stock) — — — —
Sun Pharmaceutical Ind L 444,405 35.2 5.32 16.0%
Divi S Laboratories Ltd 255,487 85.8 15.25 16.5%
Torrent Pharmaceuticals L 189,746 85.0 20.11 27.4%
Apollo Hospitals Enter. L 128,055 60.9 13.51 21.2%
Zydus Lifesciences Ltd 120,089 24.7 4.48 21.2%
Cipla Ltd 111,060 31.0 3.23 11.6%

Which Mutual Funds Hold Anuh Pharma Limited?

Frequently Asked Questions about Anuh Pharma Limited

Community Sentiment

What are other investors saying about Anuh Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.